OR WAIT 15 SECS
Johnson & Johnson announced the acquisition of Alios BioPharma to expand their portfolio of therapeutics for viral infections.
Johnson & Johnson announced on Sept. 30, 2014 that they have reached an agreement to acquire Alios BioPharma, a clinical-stage biopharmaceutical company that develops therapies for viral diseases, with a specialization in viral respiratory disease therapies. The $1.75 billion acquisition of Alios includes the compound AL-8176, an oral, anti-respiratory syncytial virus (RSV) nucleoside analog currently in Phase IIa studies.
“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, MD, PhD, global head, research & development, Janssen Pharmaceutical Companies of Johnson & Johnson. “AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”
Related Content:PharmTech News